Dr. Reddy's Laboratories Limited — Important, 09-05-2025: General Updates

Dr. Reddy's has announced a board meeting to discuss the financial results for the quarter and half-year. The Board approved a final dividend of Rs. 8 per share for FY25 and re-appointed Mr. G V Prasad as Co-Chairman & Managing Director for five years starting January 2026. Key highlights include integration of Haleon's Nicotine Replacement Therapy portfolio, partnerships for biosimilars, and strong growth in Global Generics (23% YoY) and Pharmaceutical Services & Active Ingredients (16% YoY). FY25 consolidated revenue rose 17% to Rs. 32,553 Cr, PBT grew 7% to Rs. 7,678 Cr, and PAT increased 2% to Rs. 5,654 Cr. Impairment charges of ~Rs. 169 Cr impacted earnings. Net cash surplus is Rs. 2,454 Cr with net debt to equity at (0.07). R&D remains robust at 8.4% of revenue, supporting new product launches and geographic expansion.